FDA Approves Novartis’ CAR-T cell therapy Kymriah™ for specific A.L.L. Patients

The US Food and Drug Administration (FDA) has approved the first CAR-T cell therapy for patients diagnosed with B-cell precursor acute lymphoblastic leukemia (A.L.L.) that is refractory or in second or later relapse. This is the first CAR-T cell therapy approved by the FDA.  More details are available in the press release issued by the Novartis Pharmaceutical Corporation.

Category Tag(s): Current News